Published in Blood Weekly, November 8th, 1999
Blood transfusion may diminish survival following curative surgery for solid tumors. This may be related to extracellular content of cancer growth factors present in the transfusion components. VEGF is a potent stimulator of angiogenesis in solid tumors.
Hans Jorgen Nielsen, of Denmark's University of Copenhagen, and colleagues performed a study to determine the potential content of soluble vascular endothelial growth factor (sVEGF) in various blood components for transfusion ("Soluble Vascular...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.